ライフサイエンスコーパス: recombinant vaccine

1 ed the best candidates for generation of the recombinant vaccine.

2 es that would be suitable for inclusion in a recombinant vaccine.

3 ore intranasal booster immunization with the recombinant vaccine.

4 results may explain the high potency of the recombinant vaccine.

5 llowed researchers to engineer synthetic and recombinant vaccines.

6 er alternative to DryVax and as a vector for recombinant vaccines.

7 ad to improvements in expression vectors and recombinant vaccines.

8 and other poxviruses as human and veterinary recombinant vaccines.

9 vaccines for smallpox- and poxvirus-vectored recombinant vaccines.

10 udies as well as for the development of live recombinant vaccines.

11 y improve the in vivo therapeutic potency of recombinant vaccines.

12 support for the development of an effective recombinant vaccine against hookworm infection in humans

13 ration in efforts to generate antibody-based recombinant vaccines against HCV.

14 r technology for the production of VLP-based recombinant vaccines against infectious diseases.

15 igning a new generation of live, attenuated, recombinant vaccines against the New World alphaviruses.

16 Both recombinant vaccines also protected against the developm

17 The recombinant vaccine ALVAC-CEA seems to be safe and has b

18 interfering RNAs (DI-RNAs) are generated by recombinant vaccine and wild-type MVs immediately after

19 s been used as the foundation for developing recombinant vaccines and has been used extensively on vi

20 iruses have long been considered vectors for recombinant vaccines and oncolytic therapies.

21 These data should aid in the design of recombinant vaccine antigens to prevent the spread of th

22 rate strong T cell immunity with purified or recombinant vaccine antigens.

23 The fact that the NYVAC-SIV recombinant vaccine appears to be effective per se in th

24 tinued development of the replicating Ad-HIV recombinant vaccine approach and suggest that the use of

25 The recombinant vaccines are the first vaccines against TB m

26 reduced in animals that received the MVA-SIV recombinant vaccines as compared with animals that recei

27 have developed, including the production of recombinant vaccines, auxotrophic vaccines, DNA vaccines

28 A recombinant vaccine based on fusion of the circumsporozo

29 s a proof of concept we developed a bivalent recombinant vaccine based on vesicular stomatitis virus

30 hich will very likely impair the efficacy of recombinant vaccines based on the homologous virus.

31 the immunogenicities of single-cycle HIV/SIV recombinant vaccines before initiating studies with nonh

32 Our initial recombinant vaccine, BNSP333-S, expresses a full-length

33 One recombinant vaccine, bvMSP1(42), based on the 42-kDa C-t

34 ese results suggest that a second-generation recombinant vaccine can be rationally engineered to maxi

35 hat vaccination with a parainfluenza virus 5 recombinant vaccine candidate expressing NA (PIV5-NA) fr

36 a challenging task and, to date, protective recombinant vaccine candidates have not been identified.

37 to soluble worm antigen preparation and the recombinant vaccine candidates rSj97, rSj67, and rSj22 f

38 in shaping the glycan epitopes presented on recombinant vaccine candidates.

39 reduced in animals that received the MVA-SIV recombinant vaccines compared with animals that received

40 mmunized systemically or intranasally with a recombinant vaccine composed of domain A of ClfB exhibit

41 We assessed the efficacy of a recombinant vaccine consisting of outer-surface protein

42 ChimeriVax-WN02 is a live, attenuated recombinant vaccine constructed from an infectious clone

43 A recombinant vaccine containing Aventis Pasteur's canaryp

44 Recombinant vaccines derived from the facultative intrac

45 ve cases of poliomyelitis due to type 2 or 3 recombinant vaccine-derived polioviruses (VDPVs) were re

46 ng that this region may be useful for future recombinant vaccine design.

47 The recombinant vaccine, designated ALVAC-CEA, was administe

48 ue for the inclusion of multiple antigens in recombinant vaccine designs.

49 present technological challenges for simple recombinant vaccine development where a multicomponent m

50 uate various VACV vectors for the purpose of recombinant vaccine development.

51 lopment of a novel "immunologically optimal" recombinant vaccine expressed in Escherichia coli that e

52 e-in-water emulsion), 2 doses of a canarypox recombinant vaccine expressing CMVgB (ALVAC-CMVgB) follo

53 emic immunization with two human ALVAC-HIV-1 recombinant vaccines expressing Gag, Pol, and gp120 (vCP

54 Recent work on the development of a recombinant vaccine for leishmaniasis has demonstrated t

55 The overall efficacy of a recombinant vaccine for Lyme disease that is effective w

56 denoviral vectors (rAds) are the most potent recombinant vaccines for eliciting CD8(+) T cell-mediate

57 eplicons may be useful in the development of recombinant vaccines for infectious diseases and cancer.

58 The response to recombinant vaccines for Lyme disease was studied to det

59 refining OspA-based vaccines and developing recombinant vaccines for other diseases.

60 , we have developed two safe and efficacious recombinant vaccines for RVF.

61 novel triple antigen (S, pre-S1, and pre-S2) recombinant vaccine (Hepacare; Medeva Pharma Plc, Speke,

62 Transgenic plants expressing recombinant vaccine immunogens offer an attractive and p

63 urther clinical exploration of the ALVAC-CEA recombinant vaccine in phase I/II studies in protocols d

64 in human vaccinations of using two different recombinant vaccines in diversified prime-and-boost regi

65 so an attractive option for glycoengineering recombinant vaccines in Escherichia coli.

66 the last 25 years, the technology to produce recombinant vaccines in plant cells has evolved from mod

67 l increase the practicality of administering recombinant vaccines mucosally.

68 Analogous results were obtained with recombinant vaccines of the same amino acid sequences.

69 unized with vaccine or a control nonvectored recombinant vaccine or HBsAg-expressing vectored MV rema

70 novel triple-antigen (S, pre-S1, and pre-S2) recombinant vaccine or of a present single-antigen (S on

71 (VSV) has long been regarded as a promising recombinant vaccine platform and oncolytic agent but has

72 Microbial KBMA vaccines used either as a recombinant vaccine platform or as a modified form of th

73 man papillomavirus (types 6, 11, 16, and 18) recombinant vaccine (qHPV) in the United States for use

74 influenza A (H3N2 and H1N1) and B virus or a recombinant vaccine (rHAO) containing 15, 45, or 135 mic

75 mbinant bivalent vaccine candidates based on recombinant vaccine strain rabies virus particles, which

76 Z1) for attenuation purposes, generating the recombinant vaccine strains SLT17 (pCZ1) and SLT18 (pCZ1

77 oliovirus live virus vectors are a candidate recombinant vaccine system.

78 ultimately impact human health by advancing recombinant vaccine technology.

79 A recombinant vaccine that mimics the native trimer might

80 Canarypox-CMV pp65 is the first recombinant vaccine to elicit CMV-specific CTL responses

81 This thus impairs the ability of recombinant vaccines to serve as factories to produce re

82 OspA is now the basis of a first generation recombinant vaccine undergoing phase III efficacy studie

83 support for the use of L. monocytogenes as a recombinant vaccine vector and show that antivector immu

84 tion with an antigenically complex virus and recombinant vaccine vector.

85 avipoxviruses), which have been developed as recombinant vaccine vectors for permissive (i.e., poultr

86 In addition, many new recombinant vaccine vectors such as vaccinia, Listeria s

87 of IL-4 contributes to immune suppression, a recombinant vaccine virus was created which secretes cot

88 dengue serotype-2 virus (DENVax-2) and three recombinant vaccine viruses expressing the prM and E str

89 tegy for the rapid development of comparable recombinant vaccine viruses for human PIV1 and PIV2.

90 The protective efficacy of the recombinant vaccines, with or without an adjuvant, was t